SUNHO BIO-B (02898) Appoints Zheng Zheng Risk Management Consulting as Independent Internal Control Advisor

Stock News
08/04

On August 4, 2026, SUNHO BIO-B (02898) announced the appointment of Zheng Zheng Risk Management Consulting Services Limited as an independent internal control advisor, based on a recommendation from the audit committee, to conduct an independent internal control review.

The independent internal control review is proposed to be carried out in three main phases: (i) a preliminary assessment to understand the group's existing internal control framework; (ii) an in-depth review to identify control deficiencies and recommend remedial measures; and (iii) a follow-up review to assess the effectiveness of the implemented remedial measures.

The independent internal control review will cover the internal control systems across all key areas of the group, including financial reporting, procurement, sales, cash management, prepayment management, research and development, outsourcing, contract management, compliance with listing rules, and other significant operational and governance processes.

免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。

熱議股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10